April 13, 2012 --China Cord Blood Corp., the largest operator of cord blood banks in China, raised $65 million in new cash from Kohlberg Kravis Roberts. KKR made the investment through its China Growth Fund LLP, which bought $65 million of 5-year convertible bonds. It is the fund’s first healthcare investment. The bonds pay 7% face amount, though other conditions can increase that rate, and they convert into common stock at roughly today’s market price. More details....
Stock Symbol: (NYSE: CO)
